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FRETThe mineralocorticoid receptor (MR), a ligand-activated transcription factor expressed in various cell types
(e.g. epithelial cells, neurons, smooth muscle cells, immune cells), plays important roles in neurohumoral,
neuronal, cardiovascular, renal and intestinal function. Pathophysiological relevant signaling mechanisms
include nongenomic pathways involving the EGF receptor (EGFR). We investigated whether a MR–EGFR
colocalization may underlie the functional MR–EGFR interaction by coimmunoprecipitation, ﬂuorescence
resonance energy transfer (FRET) and confocal microscopy in a heterologous expression system. EGFR and a
small fraction of MR colocalize at the cell membrane, independently of short time exposure (≤60 min) to
receptor ligands. Twenty-four-hour-exposure to saturating concentrations of aldosterone (10 nmol/l)
resulted in an almost complete nuclear translocation of MR and disappearance of MR–EGFR colocalization.
EGFR transactivation is enhanced only after MR stimulation. Inhibition of HSP90 by geldanamycin did not
reduce the fraction of MR interacting with EGFR. Disruption of cholesterol-rich membrane domains by
cyclodextrin reduced MR–EGFR interaction. In conclusion, a subfraction of MR interacts with EGFR at the
plasma membrane in our heterologous expression system, possibly at cholesterol-rich domains, to form a
steroid receptor/growth factor receptor signaling module.Physiologie, Universität Halle-
, Germany. Tel.: +49 345 557
(M. Gekle).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Themineralocorticoid receptor (MR) belongs to the steroid receptor
family and is usually described as a ligand-inducible transcription factor,
controlling the expression of target genes involved e.g. in Na+ and K+
homeostasis aswell as blood pressure regulation and tissue remodeling
[1,2]. MR promotes pathological alterations of cardiovascular and renal
tissue homeostasis, independently of its effects on blood pressure or
NaCl homeostasis [3–5].
Nowadays the existence of nongenomic signaling pathways of
steroid hormone receptors – including themineralocorticoid receptor –
is well accepted [6,7] and these pathways are of potentially pathological
relevance [8–10]. Nongenomic signaling ofMR – similar to other steroid
hormone receptors – relies on a crosstalk with other cytosolic signaling
cascades. In recent years, the prominent role of the EGF receptor (EGFR)
inmediating at least part of nongenomicMR signaling and possibly of its
pathological actions has been characterized functionally [9,11–16].
Stimulation of MR leads to a rapid EGFR transactivation [17,18]. Sub-
sequently, cytosolic signaling cascades are activated, including extra-
cellular regulated kinase (ERK1/2), Rho kinase or p38 kinase, which
may transduce the signal into the nucleus via the transcription factors
AP1 and NFkB [8,18–20], thereby eliciting an indirect genomic action.Functional data indicated that there is the possibility of a constitutive
interaction of MREF with EGFR in the apparent absence of ligand [8].
Such an interaction could be explained by the colocalization of a small
subset of MR with the EGFR at the plasma membrane [8]. Accordingly,
Ziera et al. detected MR in the membrane protein fraction of HEK cells
transfected with MR [21].
Likewise, the classical receptors for estrogens (ER), progesterone
(PR), androgens (AR) andglucocorticoids (GR) alsomediate at least part
of their nongenomic effects [6,7,22–29] via a receptor fraction located in
or at the plasma membrane (e.g. ER, [30–32]) that interacts with the
EGFR. Localization of the small ER subfraction at the cell membrane
depends on the E-domain and seems to occur as monomer [31].
Thus, EGFR serves as a relay station to transducenongenomic steroid
receptor signaling. However, it is not clear whether a subpopulation of
steroid receptors is organized in an EGFR signaling microdomain,
possibly at theplasmamembrane. The functional importanceof a spatial
organization at the plasma membrane for rapid aldosterone/MR
signaling has been suggested for pathophysiological effects in vascular
smooth muscle cells [33].
In the present study, we addressed this question for the MR using
immunoprecipitation, FRET and confocal microscopy. Our data contrib-
ute to further our understanding of non-genomic signaling of steroid
receptors by suggesting that a small subpopulation of MR colocalizes
withEGFR in a signalingmicrodomain at theplasmamembrane.Of note,
our study describes the interaction in a model with heterologous MR
expression. Future studies will have to investigate the interaction of
endogenously expressed MR with EGFR.
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2.1. Cell culture
Cell culture with HEK-293 cells was performed as described
previously [8].
2.2. Constructs and transfection
Transfection of the cells was performed under serum-free con-
ditions as described before [8,19] with the Qiagen Polyfect reagent
(Qiagen, Hilden, Germany), according to the manufacturer's instruc-
tions. Experiments were performed 48 h after transfection. We used
the expression vectors pEYFP-C1-hMR ([34]), pEYFP, pcDNA3.1-hMR,
pcDNA3.1-LacZ (Invitrogen). pcDNA3.1 vector contains a Xpress tag.
Construction of the truncated versions of the hMR, which lack either
the N-terminal AB-domain (hMRCDEF), the AB-domain and the DNA-
binding domain (hMRDEF) or additionally the hinge region (hMREF)
has been described previously [8]. To exclude that the tags modify the
characteristics of the receptor, we compared GRE activation and
nuclear translocation properties of tagged and untaggedMR but could
not ﬁnd signiﬁcant differences [19,34].
2.3. Immunoprecipitation and Western blot analysis
Cells were washed, harvested and lysed in RIPA buffer [35]. Lysates
were then centrifuged at 11000 rpm at 4 °C for 10 min and the
supernatant was incubated over night with EGFP or EGFR antibody
(Santa Cruz Biotechnology Inc.) with end-over-end rotation and then
with A/G plus agarose for another 24 h. After 10 min of centrifugation
at 10000 rpm at 4 °C, the pellet was mixed with 40 µl Laemmli buffer
and separated by an 8% SDS-PAGE gel.
2.3.1. Western blot analysis
Cell lysates were matched for protein content, separated by SDS-
PAGE and transferred to a nitrocellulose membrane. Subsequently
membranes were blotted with the respective antibodies (anti-EGFP,
anti-EGFR, anti-pTyr or anti-MR from Santa Cruz; anti-Xpress from
Invitrogen). The bound primary antibody was visualized using
horseradish peroxidase-conjugated secondary IgG and the ECL system
(Amersham Corp.). Densitometry analysis was performed with Quan-
tity One (Biorad).
2.4. Immunoﬂuorescence and confocal microscopy
Cells transfected with EGFP-hMR were cultivated on glass cover
slips, ﬁxed with 4% formaldehyde (15 min), washed three times with
PBS and permeabilized with 0.5% Triton-X100. Subsequently, cells
were incubated for 10 min in 1% SDS/PBS, followed by 10 min
100 mmol/l glycine/PBS and ﬁnally for 20 min in 10% serum/1% BSA/
PBS. After 60 min incubation with anti-EGFR, the cells were washedFig. 1. FRET determination. Scheme showing the procedure applied to obtainthree times with PBS and incubated for 45 min with anti-rabbit-
Alexa568 secondary antibody or non-labeled secondary antibody.
After three further washes, the cells were analyzed by confocal
microscopy (Radiance 2000, Bio-Rad) and the images were processed
using the software MetaMorph Imaging System (Microsoft).
Quantitative evaluation was performed in a blinded fashion. The
observer ﬁrst identiﬁed cells successfully transfected with EGFP or
EGFP-MR and stained for EGFR (for an example see Fig. 4) and
determined the percentage of cells showing colocalization (yellow).
The results were analyzed by the Chi2-test. Two hundred cells were
evaluated.
2.5. Fluorescence resonance energy transfer (FRET)
Cells were cultivated in 96-well plates and transfected with the
mentioned EYFP-labeled constructs as described above. After 48 h,
cells were incubated for an additional 60 min with the compounds
given in the text or vehicle. Subsequently, cells werewashedwith PBS,
ﬁxed (4% paraformaldehyde, 60 min at 21 °C) and permeabilized
(0.1% Triton X-100). After 60 min incubation in blocking solution (0.1
% Triton X-100 in TBS+5% BSA), cells were incubated overnight with
anti-EGFR (Santa Cruz; 1:100, 4 °C) or control solution. After three
washes with blocking solution, cells were incubated for 60 min with
anti-rabbit-Alexa568 secondary antibody (1:100). After another three
washes, the following ﬂuorescence values (Fexcitation/emission) were
measured using the Inﬁnite 200 Multiwell Reader (Tecan), which
supports the FRET detection mode (Fig. 1): F490/535 (Em1 for EYFP),
F535/610 (Em2 for Alexa568, i.e. EGFR) and F490/610 (Em3 for FRET
determination). The mentioned excitation and emission wavelengths
were set by two prisms with a bandpass of 9 nm for excitation and
15 nm for emission.
FRET efﬁciency was calculated from the ﬂuorescence values after
background subtraction as follows:
For each experiment, a set of cells not expressing the EYFP label was
measured. The obtained F490/610 valuewas used to determine the relative
spill-over of Alexa568 emission during FRET determination (= Em2′;
20.4±0.5%). Emission during FRET determination (Em3) was corrected
for this spill-over (Em3′=Em3−Em2′). Next the ﬂuorescence emission
ratio Em3′/Em1 (FR610/535), which is a measure for the Alexa568
(i.e. EGFR) ﬂuorescence elicited by the EYFP emission, was calculated. In
order to obtain the true FRET610/535, the values obtained from EYFP or
EYFP-MR expressing cells in the absence of anti-EGFR (resulting from
EYFP spill-over) were subtracted from the values in the presence of anti-
EGFR (FRET610/535=FR610/535+Anti-EGFR−FR610/535−Anti-EGFR). Finally, we determined
FRET610/535 for EYFP and EYFP-MR under all experimental condition to
obtain the MR-dependent FRET signal.
2.6. Reporter gene assay
Transactivation was assessed by the Mercury® Pathway Proﬁling
reporter gene assay system from Clontech Inc. using secretory alkalinean MR-dependent FRET signal. For details see Materials and methods.
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element) cis-regulatory response elements as reporter, essentially as
described earlier [36,37]. In brief, the cells were cotransfected with
pGRE-SEAP and hMR or empty vector. SEAP-activity in the media
was determined with the AttoPhos® System from Promega
(Mannheim, Germany) and normalized to the transfection control
(beta-galactosidase).
2.7. Statistics
The data are presented as mean values±SEM. Signiﬁcance of
difference was tested by paired or unpaired Student's t-test, ANOVA
or Chi2-test as applicable. Differences were considered signiﬁcant if
pb0.05. Cells from at least two different passages were used for each
experimental series. N represents the number of tissue culture dishes
investigated.
3. Results
3.1. Coimmunoprecipitation of MR and EGFR
As shownbefore [8,19]wild typeHEK cells donot express detectable
MRbut are readily transfectable. In cells transfectedwithhumanMR,we
detected EGFR in anti-MR immunoprecipitates (Fig. 2A). This was not
the case in cells transfectedwith the empty vector. These data show thatFig. 2. Coimmunoprecipitation. (A) HEK cell transfected with EGFP-MR andwild type cells we
cells expressing MR, independently of aldosterone (60 min incubation). (B) HEK cell transfec
EGFP, the EGFR was detected only in cells expressing MR, independently of aldosterone.
immunoprecipitation with anti-EGFR, the relative amount of Xpress-MR in the precipitate wa
of aldosterone (60 min exposure). pEGFR=Tyr-phosphorylated EGFR. (D) Coimmunoprecip
for 24 h, indicating that the MR is not stably associated with the cell membrane but detach
EGFP-MRDEF, EGFP-MREF or with EGFP were compared. After immunoprecipitation with anti-
but not in cells expressing EGFP. The insert shows that the cells used express detectable leve
EGFR in cells expressing EGFP-MRDEF or EGFP-MREF was independent of aldosterone.EGFR coimmunoprecipitates with MR, indicating a physical interaction
of the two receptors. In our coimmunoprecipitation experiments, this
interactionwas not enhanced by theMR agonist aldosterone (10 nmol/
l, 60 min exposure, Fig. 2A). To exclude a non-speciﬁc interaction with
the EGFP-tag, we compared cell expressing EGFP-MR with cells
expressing EGFP. As shown in Fig. 2B, EGFR coimmunoprecipitation
occurred only when EGFP-MR was expressed, excluding an interaction
with the EGFP-tag.
Next, we precipitated EGFR and determined coimmunoprecipitation
using Xpress-tagged MR. To exclude non-speciﬁc interactions with the
Xpress-tag, we compared cell expressing Xpress-MR with cells expres-
sing Xpress-beta-Gal. As shown in Fig. 2C, Xpress-MR was coimmuno-
precipitated with EGFR, again independent of aldosterone. We also
detected traces of Xpress-beta-Gal, most probably resulting from
incompletewashing. Comparison of the IP/lysate-ratio for both proteins
(Fig. 2C) shows that there is a signiﬁcant coimmunoprecipitation of
Xpress-MR.
As already mentioned, the coimmunoprecipitation results were not
affectedbyMRactivationwithaldosterone (10 nmol/l, 60 minexposure).
In contrast, aldosterone enhanced EGFR tyrosine-phosphorylation in cells
expressing MR, but not in controls (Fig. 2C). These data indicate that a
fractionofMRcolocalizeswithEGFR irrespectiveofMRactivationbut that
MR-induced EGFR transactivation is enhanced by aldosterone. When we
exposed the cells for 24 h to aldosterone, no coimmunoprecipitation of
MR and EGFR was observed (Fig. 2D). These ﬁndings indicate that there compared. After immunoprecipitation with anti-EGFP, the EGFRwas detected only in
ted with EGFP-MR or with EGFP were compared. After immunoprecipitation with anti-
(C) HEK cells transfected with Xpress-MR or Xpress-beta-Gal were compared. After
s signiﬁcantly larger as compared to Xpress-beta-Gal. Again, the effect was independent
itation of MR and EGFR was not observed in cells that had been exposed to aldosterone
es with slow kinetics after ligand binding. (E) HEK cell transfected with EGFP-MRCDEF,
EGFP, the EGFR was detected in cells expressing EGFP-MRCDEF, EGFP-MRDEF, EGFP-MREF
ls of HER2 only after transfection with a HER2 construct. (F) Coimmunoprecipitation of
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slowly and are in agreementwith the previously observed disappearance
of MR from the membrane fraction of HEK-MR cells after prolonged
aldosterone exposure [21].
Finally, we performed coimmunoprecipitation experiments using
truncatedMRvariants [8]. The results presented in Fig. 2E and F indicate
that the MR-domains EF are sufﬁcient for the receptor colocalization.
When we used the MR-construct consisting of the domains A and B,
which has previously been shown not to elicit non-genotropic
actions of aldosterone, we did not observe any coimmunoprecipita-
tion of EGFR.
In Fig. 2E, EGFR seems to present with a double band. In order to
exclude that HER2 was detected incidentally, we determined HER2
expression in our cells using the HER2-antibody from Santa Cruz (sc-
284). As shown in the insert in Fig. 2D, HER2was detected only in HEK
cells transfected with a HER2 construct (kindly provided by Dr.
J. Troppmaier, University of Innsbruck, Austria). These data exclude
the possibility of crossreactivity with HER2.3.2. FRET of MR and EGFR
To investigate the hypothesis ofMR–EGFR colocalization by a second,
independent technique, we applied FRET analysis as described in the
Materials and methods section. Since we used an antibody approach to
label EGFR, a positive FRET value by itselfwould not allow the conclusion
that the two receptors localizewithin a distance of≤10 nmbecause the
antibody could bridge a certain gap. Nevertheless, the conclusion of
localization in closeproximity is justiﬁed. Fig. 3A shows theﬂuorescence
emission ratio FR610/535 for cells expressing either EYFP or EYFP-MR in
the absence or presence of EGFR labeling. The values obtained for EYFP
with or without EGFR labeling and for EYFP-MR without EGFR labeling
showed no statistical signiﬁcant difference. In contrast, the value for
EYFP-MR with EGFR labeling was statistically signiﬁcantly higher. The
differences in FR610/535 with and without EGFR labeling yield the
FRET610/535 values, shown in Fig. 3B, which are signiﬁcantly different
from 0 only for EYFP-MR. MR-dependent FRET is shown in Fig. 3C.
Similar to the coimmunoprecipitation results, aldosterone did not affect
MR–EGFR colocalization within 60 min (Fig. 3D). In a separate set ofFig. 3. FRET results. (A) Fluorescence emission ratio FR610/535 for cells expressing either EYFP
The differences in FR610/535 with and without EGFR labeling, yielding the FRET610/535 values ar
values for EYFP alone, are shown. (D)Effect of aldosterone (10 nmol/l), geldanamycin (2 µmol/l
FRET610/535 values. N=9–25. ⁎=pb0.05 versus control (=vehicle). Cells were incubated forexperiments,we investigated the time-course ofMR-dependent FRET in
the presence of 10 nmol/l aldosterone. As shown in Fig. 3D, aldosterone
induced a signiﬁcant decrease of the MR-dependent FRET signal
after 120 min and 24 h exposure (Fig. 3D). After 24 h exposure, the
FRET signal was no longer statistically signiﬁcantly different from
background.
The MR antagonist spironolactone (1 µmol/l; Fig. 3D) reduced
colocalization in part whereas EGF (100 µg/l; Fig. 3D) exerted no
signiﬁcant effect.
Inhibition of the chaperone HSP90 with geldanamycin (2 µmol/l),
which is supposed to result in HSP90-MR dissociation, did not reduce
the FRET signal (Fig. 3D). In contrast, geldanamycin abrogated
aldosterone-induced MR transactivation activity (6.1±0.2-fold in the
absence and 0.9±0.1-fold in the presence of geldanamycin, N=12).
From these data, we conclude that HSP90 is not required for the
colocalization of MR and EGFR. MR-dependent FRET610/535 values
signiﬁcantly different from0were also obtained for theMREF construct
(0.012±0.003, N=5), conﬁrming the coimmunoprecipitation results
(Fig. 2F).
Cyclodextrin (10 mg/l), which depletes the plasma membrane of
cholesterol [33] reduced the MR-dependent FRET610/535 values
signiﬁcantly (Fig. 3D). Although the ﬁnal proof is still missing, these
data suggest that EGFR-MR interaction occurs at cholesterol-rich
domains (caveolae, lipid rafts).3.3. MR and EGFR colocalize at the cell membrane
Finally, we investigated the cellular site of MR–EGFR colocalization
by confocal microscopy. Fig. 4A and B show two examples of cells
transfected with EGFP-MR (green ﬂuorescence). EGFR is shown in red
(anti-rabbit-Alexa568 secondary antibody) and colocalization in yellow
(overlay images show all three colors, in the colocalization images the
red and greenwere set to zero). In the overlay and colocalization images
of Fig. 4A, a narrow yellow zone is detectable at the membranes of
adjacent cells. Theupper left cell in Fig. 4B,whichhas nodirect neighbor,
shows colocalization at the cell membrane along the entire circumfer-
ence. From these images, we conclude that colocalization of MR and
EGFR takes place mainly at the cell membrane. Fig. 4C shows cellsor EYFP-MR in the absence or presence of EGFR labeling (with anti-EGFR). N=15–30. (B)
e shown. (C) MR-dependent FRET610/535 values, obtained after subtraction of FRET610/535
), spironolactone (1 µmol/l), EGF (100 µg/l) andcyclodextrin (10 mg/l) onMR-dependent
60 min if not stated otherwise.
Fig. 4. Confocal microscopy. (A, B) Two examples of cells transfected with EGFP-MR (green ﬂuorescence). EGFR is shown in red (anti-rabbit-Alexa568 secondary antibody) and
colocalization in yellow (overlay images show all three colors, in the colocalization images the red and green were set to zero). (C) Example of cells transfected with EGFP. (D)
Colocalization of EGFR and EGFP-MR can still be observed after incubation with geldanamycin (2 µmol/l, 60 min). (E) No colocalization can be observed after 24 h of incubation with
10 nmol/l aldosterone. Scale bar=10 µm.
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(as compared to EGFP-MR), there is barely any overlay detectable.
Finally we conﬁrmed the conclusion that EGFR-MR interaction is not
affected by HSP90 inhibition with geldanamycin, drawn from the FRET
experiments. Fig. 4D shows the colocalization signal in cells treatedwith
geldanamycin (2 µmol/l) for 60 min. These data support the FRET
results shown in Fig. 3D. Fig. 3E shows, in accordance with the
immunoprecipitation and FRET data, that after prolonged exposure to a
saturating concentration of aldosterone (10 nmol/l, 24 h) no colocaliza-
tion signal is detectable and MR has translocated to the nucleus.Fig. 5 shows the quantitative analysis of the confocal images. The
percentage of cells successfully transfected and stained for EGFR that
showed colocalization (positive cells) is presented.
4. Discussion
Nowadays the existence of nongenomic effects of the mineralocor-
ticoid receptor – as well as of other steroid hormone receptors – is well
accepted [6,7,31]. However, the underlying mechanisms are not well
understood. It has been shown thatMR elicits its nongenomic effects, at
Fig. 5. Quantitative analysis of confocal images. The observer ﬁrst identiﬁed cells
successfully transfected with EGFP or EGFP-MR and stained for EGFR and subsequently
determined the percentage of cells showing colocalization. ⁎=pb0.05 versus EGFP-MR
(vehicle). Two hundred cells were analyzed.
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Therefore, the MR employs a signaling cascade similar to ER and PR
[6,22,29–31,41,42]. Recently, itwas shown that theMRalso employs the
C-terminal domains EF, which comprise the ligand-binding site of the
receptor, for nongenomic signaling [8] leading to EGFR transactivation
at the cell membrane and thereby inducing phosphorylation of ERK1/2
[15,19,43]. In addition, a ligand-independent effect of MR on ERK1/2
activation seems to exist. These nongenomic actions seem to contribute
to pathophysiological events, like enhanced collagen III abundance [8].
The data presented here extend our knowledge on the underlying
mechanisms showing that there is a colocalization of a small fraction of
MR with EGFR at the cell membrane. We are aware of the fact that our
data were generated in a heterologous expression system and have to be
extended to endogenously expressed MR and to primary cells in future.
However, these approaches are hampered by the limited availability of
suitable antibodies and the fact that the fraction ofMRat themembrane is
expected to be very small – as also shown by our results. Our data do not
exclude the possibility that the colocalization is mediated by bridging/
scaffold proteins, which form a larger signaling module containing MR
and EGFR.
The colocalization of MR and EGFR was not dependent on receptor
activation, suggesting a constitutive process. A similar ligand-indepen-
dent interaction with EGFR has been described for β1-adrenergic
receptors [44]. This process is different from heterodimerization with
the glucocorticoid receptor or homodimerization [45], which both
depend on the presence of ligands. EGFR transactivation (phosphory-
lation) was enhanced by the addition of aldosterone, indicating that
constitutive colocalization is not sufﬁcient for full functional interaction.
Possibly, hormone binding to MR elicits conformational changes
stimulating the transactivation mechanism, which may involve cSrc
kinase [10,18,19,38–40]. The mechanistic integration of cSrc in the
observed colocalization awaits future elucidation. Prolonged MR
activation with saturating concentrations of aldosterone led, as
expected, to nuclear translocation of the major fraction of the receptor.
Because under this condition MR–EGFR interaction was no longer
observed by any of the three techniques,we suggest that themembrane
fraction of MR is not stable but dissociates slowly under conditions of
maximum stimulation and also moves into the nucleus. These data are
in agreement with the previously observed disappearance of MR form
the membrane fraction of HEK-MR cells after prolonged aldosterone
exposure [21].MR does not contain a perfect palmitoylation sequence which has
been shown to be required formembrane localization of ER, PR and AR
[46]. Whether the imperfect sequence FYQLTKLL or the sequence
FPAMLVEII in the E-domain is involved in MR-targeting to the
membrane has to be determined in future studies. For this purpose,
it has to be investigated (i) whether MR is palmitoylated, (ii) where
such a palmitoylation occurs and (iii) whether it contributes to
subcellular receptor localization. Since prolonged exposure to satu-
rating concentrations of aldosterone abolished the MR–EGFR interac-
tion, the MR membrane subset is probably not stably associated with
themembrane, opening up the possibility that lipidmodiﬁcation ofMR
is not required for the observed effects. In conclusion, our data suggest
the existence of signaling microdomains at the cells membrane which
harbor MR and EGFR and may organize their nongenomic interaction.
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